Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature

Journal of Endocrinology

Volumn 155, Issue 1, 1997, Pages 79-86

  Pihoker, C ^a,d   Badger, T M ^b   Reynolds, G A ^c   Bowers, C Y ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RELEASING FACTOR; INSULIN; LEVODOPA; PRALMORELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY HEIGHT; BOLUS INJECTION; BONE AGE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RATE; HUMAN; HYPOPHYSIS; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SHORT STATURE;

ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HORMONES; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; OLIGOPEPTIDES; STATISTICS, NONPARAMETRIC;

EID: 0030821890     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1550079     Document Type: Article

References (44)

1. Bach MA, Krupa D, Taylor AM, Farmer M, Chapman I, Thorner MO & Gormley G 1996 Morning dosing with MK-0677, a GHRP-mimetic, optimizes drug-induced IGF-1 levels. Endocrine Society Program Abstracts, p 769.
2. Badger TM, Millard WJ, McCormick GF, Bowers CY & Martin JB 1984 The effects of growth hormone (GH)-releasing peprides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 115 1432-1438.
3. Baxter RC & Martin JL 1986 Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. Journal of Clinical Investigation 78 1504-1512.
4. Bercu BB, Yang S, Masuda R & Walker RF 1992 Role of selected endogenous peptides in GHRP activity: analysis of GHRH, thyroid hormone releasing hormone, and gonadotropin-releasing hormone. Endocrinology 130 2579-2586.
5. 2 stimulate growth hormone release through distinct receptor sites. Journal of Endocrinology 129 11-19.
6. 2 on GH secretion in children with short stature. Acta Endocrinologica 275 (Suppl) 135-138.
7. Bowers CY 1993 GH releasing peptides - structure and kinetics. Journal of Pediatric Endocrinology 6 21-31.
8. Bowers CY, Momany FA, Reynolds GA & Hong A 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114 1537-1545.
9. Bowers CY, Sartor AD, Reynold GA & Badger TM 1991 On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 128 2027-2035.
10. Bowers CY, Alster DK & Frentz JM 1992 The GH-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. Journal of Clinical Endocrinology and Metabolism 74 292-298.
11. Carlsson L, Mercado M, Baumann G & Stene M 1994 Assay systems for the growth hormone binding protein. Proceedings of the Society for Experimental Biology and Medicine 206 312-315.
12. Cella SG, Locatelli V, Poratelli M, DeGennaro Colonna V, Imbimbo BP, Deghenghi R & Müller EE 1995 Hexarelin, a potent GHRP analogue: interactions with GHRH and clonidine in young and aged dogs. Peptides 16 81-86.
13. Celniker AC, Chen AB, Wert RM & Sherman BM 1989 Variability in the quantitation of circulating growth hormone using commercial immunoassays. Journal of Clinical Endocrinology and Metabolism 68 469-476.
14. Codd EE, Shy AYL & Walker RF 1989 Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 28 1130-1144.
15. Codd EE, Aloyo VJ & Walker RF 1990 A non-opioid pattern characterized inhibition of growth hormone releasing peptide binding by dynorphin-related peptides. Neuropeptides 15 133-137.
16. Copeland K 1988 Effects of acute high dose and chronic low dose estrogen on plasma somatomedin-C and growth in patients with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 66 1278-1282.
17. Davis CB, Crysler CS, Boppana VK, Fong KL, Joseph GL, Urbanski U, Macia RA & Rhodes GR 1994 Disposition of GHRP (SK&F110679) in rat and dog following intravenous or subcutaneous administration. Drug Metabolism and Disposition 22 90-98
18. Dickson SL, Leng G & Robinson IC 1993 Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscicnce 53 303-306.
19. Fletcher TP, Thomas GB, Willoghby JO & Clarke IJ 1994 Constitutive growth hormone secretion in sheep after hypothalamopituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6. Neuroendocrinology 60 76-86.
20. Goth MI, Lyons CE, Canny BJ & Thorner MO 1992 Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130 939-944.
21. Hintz RL, Liu F, Chang D & Seegan G 1988 A sensitive radioimmunoassay for somatomedin-C/insulin-like growth factor-1 based on synthetic insulin-like growth factor 57-70. Hormone and Metabolic Research 20 344-347.
22. 2 in children with GH deficiency: effects on GH secretion and growth. Acta Paediatrica (Supplement) 388 23-26.
23. Kearns GL, Kemp SF & Frindik JP 1991 Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 72 1148-1156.
24. Kemp SF 1996 Growth hormone therapeutic practice: dosing issues. The Endocrinologist 5 231-237.
25. Laron Z, Bowers CY, Hirsch D, Almonte AS, Pelz M, Keret R & Gil-Ad I 1993 GH releasing activity of GHRP-1 (a synthetic heptapeptide) in children and adolescents. Acta Endocrinologica 129 424-426.
26. Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon F, Lengerts V & Deghenghi R 1994 Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clinical Endocrinology 41 539-541.
27. Laron Z, Frenkel J, Eshet R, Klinger B & Silbergeld A 1995 Human growth honnone and insulin-like growth factor-I stimulating and growth promoting effects by long term intranasal administration of the hexapeptide hexarelin. Endocrine Society Program Abstracts, p 504.
28. 2 Journal of Clinical Endocrinology and Metabolism 75 1255-1260.
29. Low LCK 1993 The therapeutic use of GHRH. Journal of Pediatric Endocrinology 6 15-20.
30. Mandel S, Moreland E, Nichols V, Hanna C & LaFranchi S 1995 Changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3, GH-binding protein, erythrocyte IGF-1 receptors, and growth rate during GH treatment. Journal of Clinical Endocrinology and Metabolism 80 190-194.
31. Martha PM, Reiter EO, Davilla N, Shaw MA, Holcombe JH & Baumann G 1992 Serum GH-binding protein/receptor: an important determinant of GH responsiveness. Journal of Clinical Endocrinology and Metabolism 75 1464-1469.
32. Mericq V, Cassorla F, Garcia H, Avila A, Bowers CY & Merriam GR 1995a GH responses to GHRP and to GHRH in GH-deficient children. Journal of Clinical Endocrinology and Metabolism 80 1681-1684.
33. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY & Merriam GR 1995b Increased growth velocity during prolonged GHRP-2 administration to growth hormone deficient children. Endocrine Society Program Abstracts, p 85.
34. Momany FA, Bowers CY, Reynolds GA, Hong A & Newlander K 1984 Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology 114 1531-1536.
35. Patchett RA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DBR, Cheng K, Chan WWS, Butler B, Mickey G, Jacks T, Schleim K, Pong SS, Chaung LY, Chen HY, Frazier E, Leung KH, Chin SHL & Smith RG 1995 Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the USA 92 7001-7005.
36. Pihoker C, Middleton R, Reynolds GA, Bowers CY & Badger TM 1995a Diagnostic studies with intravenous and intranasal GHRP-2 in children of short stature. Journal of Clinical Endocrinology and Metabolism 80 2987-2992.
37. Pihoker C, Bowers CY, Middleton R, Reynolds GA & Badger TM 1995b Treatment effects of intranasal GHRP-2 in GH deficient children. Endocrine Society Program Abstracts, p 504.
38. Pintor C, Cella S, Loche S, Corda R, Locatelli V, Puggioni R & Muller E 1987 Clonidine treatment for short stature. Lancet i 1226-1230.
39. Saggese G, Federico G & Cinquanta L 1995 Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: Effect of short-and long-term recombinant human growth hormone administration. Pediatric Research 37 106-111.
40. Schwarz AJ, Brasel JA, Hintz RL, Mohan S & Cooper DM 1996 Acute effect of brief low-and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II and IGF-binding protein-3 and its proteolysis in young healthy men. Journal of Clinical Endocrinology and Metabolism 81 3492-3497.
41. Thorner MO, Rogol AD, Blizzard RM, Klingensmith GJ, Najjar J, Misra R, Burr I, Chao G, Martha P, McDonald J et al. 1988 Acceleration of growth rate in GH-deficient children treated with human GHRH. Pediatric Research 24 145-151.
42. Thorner M, Rochioccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P & Shah F 1996 Once daily subcutaneous growth hormone releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology and Metabolism 81 1189-1196.
43. Veeraragavan K, Sethumadhavan K & Bowers CY 1992 GHRP binding to porcine anterior pituitary and hypothalamic membranes. Life Sciences 50 1149-1155.
44. Wit JM, Rietveld DH, Drop SL, Oostdijk W, Gons M, Otten BJ, Delemarre-van de Waal HA, Reeser M, Waelkens JJ & Bot A 1989 A controlled trial of methionyl growth hormone therapy in prepubertal children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Acta Paediatrica Scandinavica 78 426-435.